Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
Get a feel for Oncodesign’s energy through relevant information about our business!
News comes to you with regular newsletters and news, teeming with vitality and ingenuity!
Customers and partners, stay in the loop about our progress for our discoveries as well as new developments related to our service offers by subscribing to our newsletter at the heart of our Services activity.
Investors and financial professionals, don’t miss out on any of Oncodesign’s financial news. Stay at the heart of our company with all our financial news, including our biannual letter to shareholders. We prepare all the information you could ever be interested in so you don’t have to!
18 rue Jean Mazen - FR - 21000 Dijon Tel.+33 380 788 260